长链非编码RNA TMEM51-AS1抑制结直肠癌进展。

Long non-coding RNA TMEM51-AS1 inhibits colorectal cancer progression.

作者信息

Wu Dongping, Xia Qing, Su Xinming, Mao Yunan, Mao Jiwei, Ding Qiannan, Liu Jianjiang, Zhong Wangyan, Zhang Xiaoyu, Li Hanbing, Duan Shiwei

机构信息

Department of Radiation Oncology, Shaoxing People's Hospital, Shaoxing, 312000, Zhejiang, China.

College of Pharmacy, Zhejiang University of Technology, Hangzhou, 310014, Zhejiang, China.

出版信息

Discov Oncol. 2025 May 23;16(1):878. doi: 10.1007/s12672-025-02676-z.

DOI:10.1007/s12672-025-02676-z

PMID:40407985

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12102048/

Abstract

Colorectal cancer (CRC) is the third most common cause of death worldwide and has high mortality and a poor prognosis. Long non-coding RNAs (lncRNAs) are non-coding RNAs longer than 200 nucleotides that play roles in cancer through multiple mechanisms. TMEM51-AS1 is a newly discovered 40,650 bp lncRNA. Our results showed that TMEM51-AS1 expression was significantly downregulated in CRC tissues (fold change = 0.74, P < 0.0001). This finding was confirmed in 20 pairs of CRC carcinoma and paracancerous tissues (fold change = 0.5, P < 0.001). Additionally, TMEM51-AS1 expression was found to be significantly reduced in CRC cell lines compared to normal human intestinal epithelial cells (P < 0.001). Bioinformatic analysis revealed that TMEM51-AS1 expression was associated with immune escape, RNA methylation, and DNA damage and repair. TMEM51-AS1 may also activate energy metabolism pathways to participate in cancer development. Drug sensitivity analysis confirmed that several drugs are more effective in CRC patients with high expression of TMEM51-AS1. In conclusion, our study demonstrates that TMEM51-AS1 can suppress the progression of CRC.

摘要

结直肠癌（CRC）是全球第三大常见死因，死亡率高且预后较差。长链非编码RNA（lncRNAs）是长度超过200个核苷酸的非编码RNA，通过多种机制在癌症中发挥作用。TMEM51-AS1是一种新发现的长度为40,650 bp的lncRNA。我们的结果显示，TMEM51-AS1在CRC组织中的表达显著下调（倍数变化=0.74，P<0.0001）。这一发现在20对CRC癌组织和癌旁组织中得到证实（倍数变化=0.5，P<0.001）。此外，与正常人肠上皮细胞相比，CRC细胞系中TMEM51-AS1的表达显著降低（P<0.001）。生物信息学分析表明，TMEM51-AS1的表达与免疫逃逸、RNA甲基化以及DNA损伤和修复有关。TMEM51-AS1也可能激活能量代谢途径以参与癌症发展。药物敏感性分析证实，几种药物对TMEM51-AS1高表达的CRC患者更有效。总之，我们的研究表明TMEM51-AS1可以抑制CRC的进展。